John Patrick Shannon Jr., Chief Executive Officer and Chairman of the Board of Xeris Biopharma Holdings, Inc., disclosed a change in beneficial ownership of common stock on August 21, 2026, reflecting a tax-withholding transaction tied to restricted stock unit vesting.

Key Highlights

  • Reporting person: John Patrick Shannon Jr., serving as Chief Executive Officer and Chairman of the Board of Xeris Biopharma Holdings, Inc.
  • Transaction date: August 1, 2026, involving common stock disposed of under transaction code F.
  • Shares withheld: 36,645 shares of common stock were withheld at a price of $8.08 per share.
  • Purpose of withholding: According to the filing, the shares represent amounts "withheld by the Issuer to satisfy its income tax and withholding and remittance obligations in connection with the net settlement of restricted stock units vested as of August 1, 2026."
  • Beneficial ownership following transaction: 2,898,933 shares of common stock held directly after the reported transaction.
  • Filing submitted: The statement was signed by Beth Hecht as Attorney-in-Fact and filed on August 21, 2026.

RSU Net Settlement Reduces CEO's Direct Share Count at Xeris Biopharma

According to the filing, John Patrick Shannon Jr. is identified as both a Director and an Officer of Xeris Biopharma Holdings, Inc. (NASDAQ:XERS), a biopharmaceutical company headquartered at 1375 West Fulton Street, Suite 1300, Chicago, Illinois 60607. The transaction reported involves common stock disposed of via transaction code F, which corresponds to shares withheld for tax purposes rather than an open-market sale.

The filing discloses that 36,645 shares were withheld by the issuer at $8.08 per share on August 1, 2026, to cover income tax and withholding obligations arising from the net settlement of restricted stock units that vested on that date. Following this withholding, Shannon's direct beneficial ownership of common stock stands at 2,898,933 shares, as reported in Table I of the filing. No derivative securities transactions were reported in Table II.

The statement was filed by one reporting person and was submitted on August 21, 2026, with Beth Hecht signing as Attorney-in-Fact. No amendment date was indicated, meaning this is an original filing. No Rule 10b5-1(c) plan checkbox was selected in connection with this transaction, according to the filing.

What Was Disclosed

The filing reports that Xeris Biopharma Holdings, Inc. withheld 36,645 shares of common stock from CEO John Patrick Shannon Jr. at $8.08 per share on August 1, 2026, to satisfy tax obligations connected to vesting restricted stock units, leaving him with 2,898,933 shares held directly.